JP2024540435A5 - - Google Patents
Info
- Publication number
- JP2024540435A5 JP2024540435A5 JP2024527544A JP2024527544A JP2024540435A5 JP 2024540435 A5 JP2024540435 A5 JP 2024540435A5 JP 2024527544 A JP2024527544 A JP 2024527544A JP 2024527544 A JP2024527544 A JP 2024527544A JP 2024540435 A5 JP2024540435 A5 JP 2024540435A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- chain variable
- variable region
- antibody
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163281024P | 2021-11-18 | 2021-11-18 | |
| US63/281,024 | 2021-11-18 | ||
| US202163287633P | 2021-12-09 | 2021-12-09 | |
| US63/287,633 | 2021-12-09 | ||
| US202263355314P | 2022-06-24 | 2022-06-24 | |
| US63/355,314 | 2022-06-24 | ||
| PCT/US2022/080131 WO2023092062A1 (en) | 2021-11-18 | 2022-11-18 | Dosing regimens of factor xi/xia antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024540435A JP2024540435A (ja) | 2024-10-31 |
| JP2024540435A5 true JP2024540435A5 (https=) | 2025-11-28 |
Family
ID=86397863
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024527544A Pending JP2024540435A (ja) | 2021-11-18 | 2022-11-18 | 第ＸＩ／ＸＩａ因子抗体の投薬レジメン |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240294669A1 (https=) |
| EP (1) | EP4433088A4 (https=) |
| JP (1) | JP2024540435A (https=) |
| KR (1) | KR20240109269A (https=) |
| CA (1) | CA3234626A1 (https=) |
| IL (1) | IL311801A (https=) |
| TW (1) | TW202334239A (https=) |
| WO (1) | WO2023092062A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230071973A1 (en) * | 2019-12-20 | 2023-03-09 | Anthos Therapeutics, Inc. | Pharmaceutical formulations and dosage regimens for factor xi/xia antibodies |
| US20250388679A1 (en) * | 2024-06-20 | 2025-12-25 | argenx BV | Subcutaneous fcrn antagonist formulations and methods of use thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6321886B2 (ja) * | 2014-05-15 | 2018-05-09 | エンジーケム ライフサイエンシーズ コーポレーションＥｎｚｙｃｈｅｍ Ｌｉｆｅｓｃｉｅｎｃｅｓ Ｃｏｒｐｏｒａｔｉｏｎ | 白血球減少症及び血小板減少症に対する治療方法 |
| UY36751A (es) * | 2015-06-26 | 2017-01-31 | Novartis Ag | Anticuerpos de factor xi y métodos de uso |
| US11066481B2 (en) * | 2015-07-23 | 2021-07-20 | The Regents Of The University Of California | Antibodies to coagulation factor XIa and uses thereof |
| TW201802121A (zh) * | 2016-05-25 | 2018-01-16 | 諾華公司 | 抗因子XI/XIa抗體之逆轉結合劑及其用途 |
| EP3713965A1 (en) * | 2017-11-22 | 2020-09-30 | Novartis AG | Reversal binding agents for anti-factor xi/xia antibodies and uses thereof |
| US20230071973A1 (en) * | 2019-12-20 | 2023-03-09 | Anthos Therapeutics, Inc. | Pharmaceutical formulations and dosage regimens for factor xi/xia antibodies |
| TW202405022A (zh) * | 2022-06-24 | 2024-02-01 | 美商安瑟斯治療公司 | 與抗因子ｘｉ／因子ｘｉａ抗體之組合療法 |
-
2022
- 2022-11-18 JP JP2024527544A patent/JP2024540435A/ja active Pending
- 2022-11-18 TW TW111144214A patent/TW202334239A/zh unknown
- 2022-11-18 EP EP22896760.0A patent/EP4433088A4/en active Pending
- 2022-11-18 KR KR1020247019707A patent/KR20240109269A/ko active Pending
- 2022-11-18 CA CA3234626A patent/CA3234626A1/en active Pending
- 2022-11-18 WO PCT/US2022/080131 patent/WO2023092062A1/en not_active Ceased
- 2022-11-18 IL IL311801A patent/IL311801A/en unknown
-
2024
- 2024-05-17 US US18/666,945 patent/US20240294669A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102886990B1 (ko) | 항-FcRn 항체를 이용한 그레이브스 안병증의 치료 방법 | |
| JP2022023051A (ja) | 瘻孔を伴うクローン病の治療用ベドリズマブ | |
| KR102553870B1 (ko) | 인간 카나비노이드 1(cb1) 수용체 결합 항체 | |
| JP2023080215A (ja) | 肝細胞癌のための免疫療法 | |
| JP2023524149A5 (https=) | ||
| TW200307690A (en) | Biological products | |
| EA033359B1 (ru) | Комбинация леналидомида и полипептидной конструкции и ее применение | |
| JP2022553851A5 (https=) | ||
| JP2024540435A5 (https=) | ||
| CN112480259B (zh) | 抗tnfr2抗体及其用途 | |
| JP2023537078A5 (https=) | ||
| CN115957321A (zh) | 一种抗her2抗体在制备治疗癌症的药物中的用途 | |
| CA3227172A1 (en) | Methods for treating acute myeloid leukemia with anti-ilt3 antibodies | |
| JP2023546504A5 (https=) | ||
| TW202108631A (zh) | 一種抗ｃｄ４７抗原結合蛋白及其應用 | |
| CN111808196B (zh) | 抗pd-1抗体及其用途 | |
| JP2025523506A (ja) | 抗第ｘｉ因子／第ｘｉａ因子抗体との併用療法 | |
| CN113993543B (zh) | 使用抗cd38抗体的组合疗法 | |
| TW202214287A (zh) | TGF-β受體的融合蛋白與多靶點酪胺酸激酶抑制劑聯合在製備治療腫瘤藥物中的用途 | |
| JP2024505195A5 (https=) | ||
| WO2021063331A1 (zh) | EZH2抑制剂与含有TGF-β受体的融合蛋白联合在制备治疗肿瘤的药物中的用途 | |
| EP4393515A1 (en) | Anti-cldn-18.2 antibody-drug conjugate and use thereof | |
| WO2026060205A1 (en) | PAN-ELR+ CXC CHEMOKINE ANTIBODIES AND IL-23p19 ANTIBODIES FOR THE TREATMENT OF ULCERATIVE COLITIS | |
| WO2024112561A1 (en) | Methods for the treatment of myasthenia gravis | |
| CN121622859A (zh) | TGF-β受体融合蛋白在制备治疗胃及胃食管结合部腺癌的药物中的用途 |